Any current/future new fundraising through debt or equity?

Solara Active Pharma Sciences is actively pursuing a rights issue planned to be completed by end of September 2023. Details of the rights issue, including use of proceeds, will be announced within 4-6 weeks from the call (August 14, 2023). A committee has been formed for the rights issue, with decisions taken at the Directors level. The purpose of the rights issue includes potential debt reduction and CAPEX plans; exact allocation to be disclosed soon. The company has set a target of 10% debt reduction for the Financial Year 2024. Debt reduction and improving cash flow through prudent capital

Any current/future capex/capital investment/strategic investment?

The company is actively working on a rights issue, with details expected by end of September, aimed at raising capital (Page 7). Proceeds from the rights issue will be used for multiple purposes including potential debt reduction, CAPEX plans, and other strategic initiatives (Page 7). Vizag facility’s utilization has improved significantly, and further CAPEX or investments to ramp up operations there are implied as the plant is expected to be fully operational in about 18 months (Page 10). The company continues to invest in R&D for expanding its generic API portfolio and CRAMS capabilities to

Future growth expectations in sales/revenue/volumes?

Solara Active Pharma Sciences has a strong order book, which has doubled compared to the previous year, indicating good visibility and demand. The company targets double-digit top-line growth in the medium term driven by operational plants like Vizag (US FDA approved) and Cuddalore facilities. Expansion focus on existing products and new product launches, including polymer-based and high-potent APIs, to improve gross margins and scale. Market expansion strategy includes tapping large global customers not previously engaged. Increased capacity utilization at Vizag is expected to significantly c

Future growth expectations in earnings/operating earnings/profits/EPS?

The company is confident about strong fundamentals driving future growth, supported by a healthy and doubled order book compared to last year. Aiming for double-digit top-line growth in the medium term, driven by US FDA approvals, capacity expansion at Vizag, and enhanced customer engagement. EBITDA margins are expected to inch back towards historical levels (early 20s %) as demand recovers and new customers enter. Focus on improving gross margins with a target of 50% or higher by optimizing product mix and supply chain efficiencies. Vizag plant utilization is improving, expected to be fully o

Current/ Expected Orderbook/ Pending Orders?

The order book has doubled compared to the same period last year. There is currently strong visibility on the order book for the coming quarters. The company sees healthy demand traction and increasing engagement with both existing and new customers globally. Solara is expanding market reach and qualifying more customers, especially with the fully operational Vizag facility. The company monitors order book and market traction closely to ensure sustainable growth momentum. The strong order book is a sign of fundamentals strengthening and improved business confidence going forward.

Solara ActiveQ1 FY24Pharmaceuticals & Biotechnology

Solara Active Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹645.65P/E: 66.2Market Cap: ₹3.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Solara Active Pharma Sciences has a strong order book, which has doubled compared to the previous year, indicating good visibility and demand.
The company targets double-digit top-line growth in the medium term driven by operational plants like Vizag (US FDA approved) and Cuddalore facilities.
Expansion focus on existing products and new product launches, including polymer-based and high-potent APIs, to improve gross margins and scale.
Market expansion strategy includes tapping large global customers not previously engaged.
Increased capacity utilization at Vizag is expected to significantly contribute to revenues within the next 18 months.
Continuous backward integration and cost improvement programs aim to enhance competitiveness and margins.
CRAMS continue to be a growth focus, though currently at 5% of revenue, with plans to expand geographically.
Overall, management is confident in sustainable growth based on strong fundamentals and improved customer traction.

Margin guidance

The company is confident about strong fundamentals driving future growth, supported by a healthy and doubled order book compared to last year.
Aiming for double-digit top-line growth in the medium term, driven by US FDA approvals, capacity expansion at Vizag, and enhanced customer engagement.
EBITDA margins are expected to inch back towards historical levels (early 20s %) as demand recovers and new customers enter.
Focus on improving gross margins with a target of 50% or higher by optimizing product mix and supply chain efficiencies.
Vizag plant utilization is improving, expected to be fully operational in ~18 months, driving revenue growth and operating leverage.
Management stability and succession planning are priorities to sustain operational efficiency and growth trajectory.
Rights issue proceeds will support debt reduction and CAPEX for growth initiatives, enhancing profitability over time.

See what Solara Active management said on margin guidance — free account, 30 seconds.

Fundraise plans

Solara Active Pharma Sciences is actively pursuing a rights issue planned to be completed by end of September 2023.
Details of the rights issue, including use of proceeds, will be announced within 4-6 weeks from the call (August 14, 2023).
A committee has been formed for the rights issue, with decisions taken at the Directors level.
The purpose of the rights issue includes potential debt reduction and CAPEX plans; exact allocation to be disclosed soon.
The company has set a target of 10% debt reduction for the Financial Year 2024.
Debt reduction and improving cash flow through prudent capital application remain priorities.
No specific new debt fundraising was mentioned beyond the focus on reducing existing debt.

Order book

The order book has doubled compared to the same period last year.
There is currently strong visibility on the order book for the coming quarters.
The company sees healthy demand traction and increasing engagement with both existing and new customers globally.
Solara is expanding market reach and qualifying more customers, especially with the fully operational Vizag facility.
The company monitors order book and market traction closely to ensure sustainable growth momentum.
The strong order book is a sign of fundamentals strengthening and improved business confidence going forward.

See what Solara Active management said on order book — free account, 30 seconds.

Capex plans

The company is actively working on a rights issue, with details expected by end of September, aimed at raising capital (Page 7).
Proceeds from the rights issue will be used for multiple purposes including potential debt reduction, CAPEX plans, and other strategic initiatives (Page 7).
Vizag facility’s utilization has improved significantly, and further CAPEX or investments to ramp up operations there are implied as the plant is expected to be fully operational in about 18 months (Page 10).
The company continues to invest in R&D for expanding its generic API portfolio and CRAMS capabilities to capture growing demand (Page 4).
Continuous backward integration and cost improvement programs are ongoing to optimize margins and reduce dependency on external suppliers (Page 12).
No specific CAPEX numbers were disclosed, but strategic investments in capacity utilization and product basket expansion are priorities.

Track Solara Active — get its next earnings analysis in your feed

How does Solara Active rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisSolara Active

See where Solara Active sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Solara Active rank in Pharmaceuticals & Biotechnology?

Compare Solara Active against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Solara Active's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →